Sol-Gel Technologies (SLGL) Cash & Current Investments (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Cash & Current Investments of $10.1 million for Q1 2026, down 39.99% year-over-year from $16.9 million in Q1 2025, and down 8.13% quarter-over-quarter from $11.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Cash & Current Investments (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Cash & Current Investments data on file, last reported at $10.1 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $10.1 million, down 39.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (down 39.99% YoY), and the FY2025 annual result was $11.0 million, down 43.42% from the prior year.
- Cash & Current Investments fell to $10.1 million in Q1 2026 per SLGL's latest filing, from $11.0 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $28.0 million in Q4 2023 and troughed at $6.2 million in Q2 2022.
- A 5-year average of $14.0 million and a median of $13.4 million in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments tumbled 80.39% in 2022, then surged 135.28% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $21.1 million in 2022, then surged by 32.46% to $28.0 million in 2023, then sank by 30.31% to $19.5 million in 2024, then slumped by 43.42% to $11.0 million in 2025, then decreased by 8.13% to $10.1 million in 2026.
- Business Quant data shows SLGL's Cash & Current Investments at $10.1 million in Q1 2026, $11.0 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 11.03 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 10.22 Mn |
| Mar 31, 2025 | 16.89 Mn |
| Dec 31, 2024 | 19.50 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 17.55 Mn |
| Mar 31, 2024 | 11.21 Mn |
| Dec 31, 2023 | 27.98 Mn |
| Sep 30, 2023 | 14.14 Mn |
| Jun 30, 2023 | 14.62 Mn |
| Mar 31, 2023 | 6.81 Mn |
| Dec 31, 2022 | 21.13 Mn |
| Sep 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 21.79 Mn |
| Sep 30, 2021 | 43.35 Mn |
| Jun 30, 2021 | 11.65 Mn |